[ Inside the business ]

MRNA stock analysis

MRNA · Moderna, Inc.

Biological products, (no diagnostic substances). Growing 29%. Loses 116¢ on every dollar.

Watch: a leadership change.

The future, in 7 questions

Priced in: 13× sales in 5 yrs. Evidence: sales +29% · loss growing.

01 What's priced in?13× sales in 5 yrs
Sales now$2.5B
Needed in 5 yrs$31.8B
Backlog$87M
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +29%, steady
FFFEnterprises 15%Public Works And Government Services Canada 13%Cardinal Health 11%Everyone else
Backlog $87M · under 0.1× salesPrepaid $407MSales +29%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Loss growing: −$1.2 per $1
'21'22'23'24'25−$1.2
Before running costs: 72% → 55%
06 Can it fund itself?4.0 yrs of cash
05 yrs10+ yrs
Shares +0.9%/yrDebt $0
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +260%, +2%, then +29% vs. a year ago. A leadership change was filed on Nov 13.

What could go wrong

Falls harder.

It has moved 1.4× the market. In the 2022 rate shock it fell 53% while the market fell 24%. Debt is covered by cash.

Speculative check

Not classified.

Not Self-funding because of: operating loss, net loss, cash from operations negative, and more. Cash runway: 4.0 years.

What they sell

95% COVID-19.

COVID-19 95% · Stand-Ready Manufacturing 2% · RSV 2% · Collaboration Arrangement, Including Arrangements With Affiliate 1% · other (latest quarter)

Where each dollar goes

116¢ loss.

72¢ to make what it sells, 144¢ on research and overhead, nothing left over. Revenue $2.5B in the last 12 months.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Introduction.

It uses cash, invests, and raises money to keep going.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

2 of 8 years.

Returns beat its 9.6% cost of capital in 2 of the last 8 years. Gross margin went from 100% to 55%.

Future bets

$24M committed.

Promised to suppliers, per its latest 10-Q. Plus $2.7B a year on research (105% of sales). Stakes in other companies: $42M.

All figures from Moderna, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.